<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROFENAL- suprofen solution </strong><br>Alcon Laboratories, Inc.<br></p></div>
<h1>Profenal® 1%<br>(Suprofen)<br>Sterile Ophthalmic Solution</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1> DESCRIPTION</h1>
<p class="First">PROFENAL® (suprofen) 1% ophthalmic solution is a topical nonsteroidal anti-inflammatory product for ophthalmic use. Suprofen chemically is α -methyl-4-(2-thienylcarbonyl)benzeneacetic acid, with an empirical formula of C<span class="Sub">14</span>H<span class="Sub">12</span>O<span class="Sub">3</span>S, and a molecular weight of 260.3. The chemical structure of suprofen is:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8de2c303-5d99-46b6-ad6d-a4caadea3604&amp;name=Profenal-01.jpg"></p>
<p>PROFENAL Sterile Ophthalmic Solution contains suprofen 1.0% (10 mg/mL), thimerosal 0.005% (0.05 mg/mL), caffeine 2% (20 mg/mL), edetate disodium, dibasic sodium phosphate, monobasic sodium phosphate, sodium chloride, sodium hydroxide and/or hydrochloric acid (to adjust pH to 7.4) and purified water.</p>
<p>DM-00</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1> CLINICAL PHARMACOLOGY</h1>
<p class="First">Suprofen is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclooxygenase enzyme that is essential in the biosynthesis of prostaglandins.</p>
<p>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed on animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.</p>
<p>Prostaglandins appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, PROFENAL has been shown to inhibit the <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> induced during the course of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery. PROFENAL could possibly interfere with the miotic effect of intraoperatively administered acetylcholine chloride.</p>
<p>Results from clinical studies indicate that PROFENAL Ophthalmic Solution has no significant effect on intraocular pressure.</p>
<p>There are no data available on the systemic absorption of ocularly applied suprofen. The oral dose of suprofen is 200 mg every four to six hours. If PROFENAL 1% Ophthalmic Solution is applied as two drops (1 mg suprofen) to one eye five times on the day prior to surgery and three times on the day of surgery, the total applied dose over the two days would be about 25 times less than a single 200 mg oral dose.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1> INDICATIONS AND USAGE</h1>
<p class="First">PROFENAL Ophthalmic Solution is indicated for inhibition of intraoperative <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1> CONTRAINDICATIONS</h1>
<p class="First">PROFENAL is contraindicated in epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>) and in individuals hypersensitive to any component of the medication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1> WARNINGS</h1>
<p class="First">The potential exists for cross sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</p>
<p>With nonsteroidal anti-inflammatory drugs, the potential exists for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span> of ocular tissues in conjunction with ocular surgery.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1> PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2> General</h2>
<p class="First">Use of oral suprofen has been associated with a syndrome of acute <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span> and generally reversible <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, which may present as acute <span class="product-label-link" type="condition" conceptid="4128219" conceptname="Urate nephropathy">uric acid nephropathy</span>. This syndrome occurs in approximately 1 in 3500 patients and has been reported with as few as one to two doses of a 200 mg capsule. If PROFENAL 1% Ophthalmic Solution is applied as two drops (1 mg suprofen) to one eye five times on the day prior to surgery and three times on the day of surgery, the total applied dose over the two days would be about 25 times less than a single 200 mg oral dose. Do not touch dropper tip to any surface, as this may contaminate the solution.</p>
</div>
<div class="Section">
<a name="section-7.2"></a><p></p>
<h2> Ocular</h2>
<p class="First">Patients with histories of <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> should be monitored closely. PROFENAL is contraindicated in patients with active <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span>.</p>
<p>The possibility of increased ocular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during surgery associated with nonsteroidal anti-inflammatory drugs should be considered.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2> Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In an 18-month study in mice, an increased incidence of benign <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatomas</span> occurred in females at a dose of 40 mg/kg/day. Male mice, treated at doses of 2, 5, 10 and 40 mg/kg/day, also had an increased incidence of <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatomas</span> when compared to control animals. No evidence of carcinogenicity was found in long term studies in doses as high as 40 mg/kg/day in the rat and mouse. Based on a battery of mutagenicity tests (Ames, micronucleus, and dominant lethal), suprofen does not appear to have mutagenic potential. Reproductive studies in rats at a dose of up to 40 mg/kg/day revealed no impairment of fertility and only slight reductions of fertility at doses of 80 mg/kg/day. However, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>/hypoplasia was observed in a six-month dog study (at 80 mg/kg/day) and a 12-month rat study (at 40 mg/kg/day).</p>
</div>
<div class="Section">
<a name="section-7.4"></a><p></p>
<h2> Pregnancy Category C</h2>
<p class="First">Reproductive studies have been performed in rabbits at doses up to 200 mg/kg/day and in rats at doses up to 80 mg/kg/day. In rats, doses of 40 mg/kg/day and above, and in rabbits, doses of 80 mg/kg/day and above, resulted in an increased incidence of fetal resorption associated with maternal toxicity. There was an increase in <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and a decrease in postnatal survival in pregnant rats treated with suprofen at 2.5 mg/kg/day and above. An increased incidence of delayed parturition occurred in rats. As there are no adequate and well-controlled studies in pregnant women, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the known effect of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2> Nursing Mothers</h2>
<p class="First">Suprofen is excreted in human milk after a single oral dose. Based on measurements of plasma and milk levels in women taking oral suprofen, the milk concentration is about 1% of the plasma level. Because systemic absorption may occur from topical ocular administration, a decision should be considered to discontinue nursing while receiving PROFENAL®, since the safety of suprofen in human neonates has not been established.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2> Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.7"></a><p></p>
<h2> Drug Interactions</h2>
<p class="First">Clinical studies with acetylcholine chloride revealed no interference, and there is no known pharmacological basis for such an interaction. However, with other topical nonsteroidal anti-inflammatory products, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with these agents.</p>
<p>Interaction of PROFENAL with other topical ophthalmic medications has not been fully investigated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1> ADVERSE REACTIONS</h1>
<div class="Section">
<a name="section-8.1"></a><p></p>
<h2> Ocular</h2>
<p class="First">The most frequent adverse reactions reported are burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> of short duration. Instances of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> have been reported. Other reactions occurring in less than 0.5% of patients include <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">chemosis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, irritation, and punctate epithelial staining.</p>
</div>
<div class="Section">
<a name="section-8.2"></a><p></p>
<h2> Systemic</h2>
<p class="First">Systemic reactions related to therapy were not reported in the clinical studies. It is known that some systemic absorption does occur with ocularly applied drugs, and that nonsteroidal anti-inflammatory drugs have been shown to increase <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> by interference with thrombocyte aggregation. It is recommended that PROFENAL be used with caution in patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies and those taking anticoagulants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1> OVERDOSAGE</h1>
<p class="First">Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1> DOSAGE AND ADMINISTRATION</h1>
<p class="First">On the day of surgery, instill two drops into the conjunctival sac at three, two and one hour prior to surgery. Two drops may be instilled into the conjunctival sac every four hours, while awake, the day preceding surgery.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1> HOW SUPPLIED</h1>
<p class="First">Sterile ophthalmic solution, 2.5 mL in plastic DROP-TAINER® dispensers.</p>
<p>2.5 mL <span class="Bold">NDC </span>0065-0348-25</p>
<p><span class="Bold">STORAGE: </span>Store at room temperature.</p>
<p><span class="Bold">Rx Only</span></p>
<p> U.S. Patents Nos. 4,035,376; 4,559,343</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8de2c303-5d99-46b6-ad6d-a4caadea3604&amp;name=Profenal-02.jpg"></p>
<p><span class="Bold">Alcon Laboratories, Inc.</span><br>Fort Worth,  Texas   76134   USA</p>
<p>Printed in  USA</p>
<p><span class="Bold">343005-0798 </span>     Revised: July 1998</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROFENAL 		
					</strong><br><span class="contentTableReg">suprofen solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0348</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>suprofen</strong> (suprofen) </td>
<td class="formItem"></td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>thimerosal</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>caffeine</strong></td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>dibasic sodium phosphate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>monobasic sodium phosphate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide and/or hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0348-25</td>
<td class="formItem">2.5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>DC62EB0C-44CF-DE50-5E26-872A270D0F6D</div>
<div>Set id: 8de2c303-5d99-46b6-ad6d-a4caadea3604</div>
<div>Version: 1</div>
<div>Effective Time: 20060223</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
